May 13 |
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
|
May 2 |
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
|
Apr 30 |
Alvotech to produce Humira biosimilar for Cigna's Quallent
|
Apr 30 |
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
|
Apr 25 |
Alvotech: Consider Buying As Positive Q1 Earnings Release Likely
|
Apr 24 |
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
|
Apr 19 |
Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S.
|
Apr 19 |
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
|
Apr 16 |
FDA approves Alvotech biosimilar of J&J top-selling drug Stelara
|
Apr 16 |
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
|